Evidence map›Paper›PMID 24778572›Full record

ReviewSarcoma2014

Sarcoma immunotherapy: past approaches and future directions.

S P D'Angelo, W D Tap, G K Schwartz, R D Carvajal

Erratum issuedOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Sarcoma, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Metabolic landscapes in sarcomas.Journal of hematology & oncology · 2021
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

S P D'AngeloDepartment of Medicine/Melanoma-Sarcoma Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA ; Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA.
W D TapDepartment of Medicine/Melanoma-Sarcoma Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA ; Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA.
G K SchwartzDepartment of Medicine/Melanoma-Sarcoma Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA ; Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA.
R D CarvajalDepartment of Medicine/Melanoma-Sarcoma Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA ; Weill Cornell Medical College, 1300 York Avenue, New York, NY 10065, USA.
Cornell University · USMemorial Sloan Kettering Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcomas are heterogeneous malignant tumors of mesenchymal origin characterized by more than 100 distinct subtypes. Unfortunately, 25-50% of patients treated with initial curative intent will develop metastatic disease. In the metastatic setting, chemotherapy rarely leads to complete and durable responses; therefore, there is a dire need for more effective therapies. Exploring immunotherapeutic strategies may be warranted. In the past, agents that stimulate the immune system such as interferon and interleukin-2 have been explored and there has been evidence of some clinical activity in selected patients. In addition, many cancer vaccines have been explored with suggestion of benefit in some patients. Building on the advancements made in other solid tumors as well as a better understanding of cancer immunology provides hope for the development of new and exciting therapies in the treatment of sarcoma. There remains promise with immunologic checkpoint blockade antibodies. Further, building on the success of autologous cell transfer in hematologic malignancies, designing chimeric antigen receptors that target antigens that are over-expressed in sarcoma provides a great deal of optimism. Exploring these avenues has the potential to make immunotherapy a real therapeutic option in this orphan disease.

Identifiers

PMID24778572
PMCPMC3981453
OpenAlexW2044422667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.